Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Bhatia A, Mehra R, Bauman J, Khan S, Wei W, Neumeister V, Sandoval‐Schaefer T, Alpaugh R, Lango M, Rimm D, Ridge J, Burtness B. Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head & Neck 2025 PMID: 40166973, DOI: 10.1002/hed.28152.Peer-Reviewed Original ResearchHead and neck squamous cell cancerProgression-free survivalEpidermal growth factor receptorTyrosine kinase inhibitorsOverall survivalPhase II trial of chemotherapyMedian progression-free survivalRecurrent squamous cell carcinomaTreatment-related adverse eventsDual epidermal growth factor receptorTreated with carboplatinPhase 2 trialPhase II trialSecondary end pointsSquamous cell cancerNuclear translocation of epidermal growth factor receptorSquamous cell carcinomaTrials of chemotherapyHead and neckSmall patient sampleTranslocation of epidermal growth factor receptorGrowth factor receptorInhibited nuclear translocationEGFR blockadeChemotherapy backbone
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply